Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bisphosphonates in multiple myeloma.

J A Kanis1, E V McCloskey

  • 1Centre for Metabolic Bone Diseases at Sheffield (World Health Organization Collaborating Centre), University of Sheffield Medical School, United Kingdom.

Cancer
|July 18, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of FRAXplus adjustments on fracture risk reclassification in older Swedish women-results from the SUPERB-study.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2025
Same author

A surrogate FRAX model for Mongolia.

Archives of osteoporosis·2025
Same author

Conflating the Operational Definition of Osteoporosis with Intervention Thresholds.

Calcified tissue international·2025
Same author

A surrogate FRAX model for Nepal.

Archives of osteoporosis·2024
Same author

An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis.

Journal of endocrinological investigation·2023
Same author

Previous fracture and subsequent fracture risk: a meta-analysis to update FRAX.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2023
Same journal

Sexual orientation and gender identity based disparities in colorectal, cervical, and breast cancer screening in the United States.

Cancer·2026
Same journal

Toward exercise as standard care for older cancer survivors.

Cancer·2026
Same journal

Maintenance therapy in gynecologic malignancies: Current and future state.

Cancer·2026
Same journal

Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

Cancer·2026
Same journal

Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

Cancer·2026
Same journal

EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

Cancer·2026
See all related articles

Bisphosphonates effectively manage skeletal complications in multiple myeloma, reducing bone pain, fractures, and hypercalcemia. These agents are a valuable addition to myeloma treatment regimens.

Area of Science:

  • Oncology
  • Pharmacology
  • Bone Biology

Background:

  • Multiple myeloma frequently causes skeletal morbidity, including bone pain and fractures.
  • Hypercalcemia is a common symptom, often linked to osteolysis driven by osteoclast-activating factors.
  • Understanding osteoclast-mediated bone remodeling supports bisphosphonate use in myeloma.

Purpose of the Study:

  • To review the role of bisphosphonates in managing multiple myeloma.
  • To assess the efficacy of bisphosphonates in treating skeletal complications associated with myeloma.

Main Methods:

  • Review of existing literature on bisphosphonate use in multiple myeloma.
  • Analysis of studies investigating bisphosphonates for hypercalcemia, bone pain, and skeletal complications.

Related Experiment Videos

Main Results:

  • Bisphosphonates are effective in correcting hypercalcemia and are the treatment of choice.
  • Intravenous bisphosphonates show benefit in acute bone pain management.
  • Long-term treatment with clodronate and pamidronate significantly reduces skeletal complications like fractures and osteolytic lesion extension.

Conclusions:

  • Bisphosphonates are a valuable adjunct therapy for multiple myeloma.
  • These agents improve management of skeletal complications and may offer survival benefits.